DWN12088 not checked
Daewoong Pharmaceutical Co. LTD.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Idiopathic Pulmonary Fibrosis
- Main trialPhase 2
- “This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.”In the company’s words, NCT05389215 on ClinicalTrials.gov
Other drugs for Idiopathic Pulmonary Fibrosis
- SC1011JOYO Pharma · Phase 2/3
- NerandomilastBoehringer Ingelheim · Phase 3
- NAL ERTrevi Therapeutics · Phase 3
- AK3280Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 3
- TDI01Beijing Tide Pharmaceutical Co., Ltd · Phase 3
- INS018_055InSilico Medicine Hong Kong Limited · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 13 Oct 2026 | Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF | |
| Phase 1Completed | 12 Jul 2021 | To Evaluate Drug-drug Interactions Between DWN12088 and Nebivolol or Paroxetine in Healthy Volunteers | |
| Phase 1Completed | 2 Aug 2021 | To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026